What is Leerink Partnrs’ Estimate for Affimed Q1 Earnings?

Affimed (NASDAQ:AFMD) – Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Affimed in a research note issued on Tuesday, December 17th. Leerink Partnrs analyst D. Graybosch expects that the biopharmaceutical company will earn ($0.59) per share for the quarter. The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share.

A number of other research firms have also recently issued reports on AFMD. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research report on Tuesday, December 10th. Stifel Nicolaus reduced their price objective on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. Finally, Wells Fargo & Company lowered their target price on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Affimed currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Affimed Stock Down 6.3 %

NASDAQ:AFMD opened at $1.18 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. Affimed has a 12 month low of $1.15 and a 12 month high of $8.95. The company’s 50-day moving average price is $2.96 and its two-hundred day moving average price is $4.10.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AFMD. Jane Street Group LLC acquired a new position in shares of Affimed during the third quarter valued at $44,000. Choreo LLC bought a new stake in Affimed during the 2nd quarter worth about $54,000. FMR LLC lifted its position in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the period. Intellectus Partners LLC lifted its position in Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the period. Finally, Point72 Asset Management L.P. boosted its stake in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the last quarter. 30.82% of the stock is currently owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.